Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
PETROCHINA
00857
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | 37.74%20.19B | 53.50%9.46B | 37.40%14.66B | 24.71%6.16B | 39.80%10.67B | --4.94B | 6.69%7.63B | --7.15B |
| Operating income | 37.74%20.19B | 53.50%9.46B | 37.40%14.66B | 24.71%6.16B | 39.80%10.67B | 4.94B | 6.69%7.63B | 7.15B |
| Cost of sales | -35.84%-18.3B | -51.09%-8.66B | -34.01%-13.47B | -20.04%-5.73B | -26.13%-10.05B | ---4.77B | 10.44%-7.97B | ---8.9B |
| Operating expenses | -35.84%-18.3B | -51.09%-8.66B | -34.01%-13.47B | -20.04%-5.73B | -26.13%-10.05B | -4.77B | 10.44%-7.97B | -8.9B |
| Gross profit | 59.34%1.89B | 85.77%796.01M | 92.72%1.19B | 160.53%428.49M | 281.54%615.4M | 164.47M | 80.59%-338.99M | -1.75B |
| Selling expenses | -47.53%-1.8B | -61.92%-840.73M | -46.13%-1.22B | -31.11%-519.24M | -30.81%-836.3M | ---396.03M | -26.32%-639.33M | ---506.1M |
| Administrative expenses | 19.79%-611.18M | -18.46%-452.62M | 36.71%-762.02M | 50.67%-382.07M | -61.87%-1.2B | ---774.49M | -116.70%-743.84M | ---343.26M |
| Research and development expenses | 12.01%-206.31M | 6.95%-116.9M | 30.93%-234.46M | 27.37%-125.64M | -50.73%-339.47M | ---172.98M | -30.05%-225.22M | ---173.19M |
| Impairment and provision | 10.54%-6.88M | 143.32%1.7M | -164.40%-7.69M | -434.10%-3.93M | 4.87%-2.91M | ---736K | 35.12%-3.06M | ---4.72M |
| -Other impairment is provision | 10.54%-6.88M | 143.32%1.7M | -164.40%-7.69M | -434.10%-3.93M | 4.87%-2.91M | ---736K | 35.12%-3.06M | ---4.72M |
| Special items of operating profit | 14.39%274.24M | 24.03%118.34M | 24.88%239.73M | 32.86%95.41M | 127.42%191.97M | --71.81M | 418.59%84.41M | ---26.5M |
| Operating profit | 42.12%-463.3M | 2.52%-494.2M | 49.19%-800.5M | 54.24%-506.98M | 15.57%-1.58B | -1.11B | 33.37%-1.87B | -2.8B |
| Financing income | -23.01%8.33M | -66.04%2.15M | -36.70%10.82M | -28.80%6.33M | 85.98%17.1M | --8.9M | -10.94%9.19M | --10.32M |
| Financing cost | 15.38%-277.52M | 11.60%-146.39M | -4.90%-327.97M | -14.16%-165.6M | -20.56%-312.64M | ---145.06M | -26.41%-259.33M | ---205.14M |
| Special items of earning before tax | 256.57%138.86M | 315.19%138.86M | -28.43%-88.69M | -8,089.34%-64.53M | -388.26%-69.06M | ---788K | -15.43%-14.14M | ---12.25M |
| Earning before tax | 50.79%-593.63M | 31.64%-499.57M | 37.82%-1.21B | 41.30%-730.78M | 8.93%-1.94B | -1.24B | 29.17%-2.13B | -3.01B |
| Tax | 50.03%-20.01M | 166.29%31.36M | 2.47%-40.05M | -75.33%-47.31M | -133.33%-41.06M | ---26.98M | 15,072.91%123.2M | --812K |
| After-tax profit from continuing operations | 50.77%-613.64M | 39.83%-468.21M | 37.08%-1.25B | 38.82%-778.09M | 1.30%-1.98B | -1.27B | 33.25%-2.01B | -3.01B |
| Earning after tax | 50.77%-613.64M | 39.83%-468.21M | 37.08%-1.25B | 38.82%-778.09M | 1.30%-1.98B | -1.27B | 33.25%-2.01B | -3.01B |
| Minority profit | 396.48%21.75M | 336.61%26.78M | 106.78%4.38M | 21.27%-11.32M | -84.32%-64.58M | ---14.37M | 37.55%-35.04M | ---56.1M |
| Profit attributable to shareholders | 49.20%-635.38M | 35.45%-494.98M | 34.74%-1.25B | 39.02%-766.78M | 2.82%-1.92B | -1.26B | 33.17%-1.97B | -2.95B |
| Basic earnings per share | 54.15%-1.27 | 35.88%-1.09 | 34.67%-2.77 | 38.85%-1.7 | 2.75%-4.24 | -2.78 | 33.23%-4.36 | -6.53 |
| Diluted earnings per share | 46.57%-1.48 | 25.88%-1.26 | 34.67%-2.77 | 38.85%-1.7 | 2.75%-4.24 | -2.78 | 33.23%-4.36 | -6.53 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
| Auditor | PwC | -- | PwC | -- | PwC | -- | PwC | PwC |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.